Instytut Podstawowych Problemów Techniki
Polskiej Akademii Nauk

Partnerzy

Jacek Gałczyński


Ostatnie publikacje
1.  Żyłka A., Dobrych-Sobczak K., Piotrzkowska-Wróblewska H. E., Jędrzejczyk M., Góralski P., Gałczyński J., Zalewska Elwirą B., Dedecjusz M., Ultrasound and cytopathological characteristics of thyroid tumours of uncertain malignant potential — from diagnosis to treatment, Endokrynologia Polska, ISSN: 0423-104X, DOI: 10.5603/ep.98488, Vol.75, No.2, pp.170-178, 2024

Streszczenie:
Introduction:
The latest World Health Organization (WHO) classification from 2022 distinguishes the division of low-risk thyroid neoplasms such as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), follicular tumour of uncertain malignant potential (FT-UMP), and well-differentiated tumour of uncertain malignant potential (WDT-UMP). The final diagnosis is made postoperatively according to histopathologic results. The aim of the study was the assessment of ultrasonographic and cytopathological features of borderline lesions to predict low-risk tumours preoperatively and plan the optimal treatment for that group of patients.

Material and methods:
A total of 35 patients (30 women; 5 men), aged 20–81 years with a mean age of 49 years, were enrolled in the study. The study evaluated 35 focal lesions of the thyroid gland, classified as low-risk neoplasms according to the WHO 2022 classification: FT-UMP (n = 21), NIFTP (n = 7), and WDT-UMP (n = 7). Ultrasonographic features of nodules including contrast-enhanced ultrasound (CEUS) and elastography were assessed by 2 specialists, and the risk of malignancy was evaluated according to EU-TIRADS-PL classification.

Results:
Of the 35 focal thyroid lesions, most were categorised as low or intermediate risk of malignancy according to EU-TIRADS-PL, with dominant category 3 [n = 13 (37.2%)] and category 4 [n = 15 (42.8%)]. High-risk category 5 was assessed in 7 lesions (20%). In cytopathology nodules were categorised as follows (Bethesda System TBSRTC 2023): Bethesda II (n = 4), Bethesda III (n = 2), Bethesda IV (n = 25), Bethesda V (n = 3), and Bethesda VI (n = 1). In the CEUS study, contrasting patterns dominated compared to the surrounding parenchyma, such as enhancement equal to the parenchyma (66.6%) or intense (28.5%), heterogeneous (61.9%), centripetal (42.8%), or diffuse (57.1%) with fast (33.3%) or compared to parenchyma contrast wash-in (42.8%) and its fast (33.3%) or comparable to thyroid parenchyma wash-out (52.3%).

Conclusions:
The study indicates that lesions with uncertain malignant potential typically present features suggesting low to intermediate risk of malignancy based on EU-TIRADS-PL classification, with dominant cytopathologic Bethesda IV category. However, 20% of lesions were assessed tas EU-TIRADS-PL category 5. Low-risk tumours, including NIFTP, FT-UMP, and WDT-UMP, require careful observation and monitoring post surgical treatment due to their potential for recurrence and metastasis. The preoperatively prediction of borderline tumour may play an important role in proper treatment and follow-up.

Słowa kluczowe:
thyroid tumour, ultrasound, thyroid cancer, contrast-enhanced-ultrasound

Afiliacje autorów:
Żyłka A. - inna afiliacja
Dobrych-Sobczak K. - inna afiliacja
Piotrzkowska-Wróblewska H. E. - IPPT PAN
Jędrzejczyk M. - inna afiliacja
Góralski P. - inna afiliacja
Gałczyński J. - inna afiliacja
Zalewska Elwirą B. - inna afiliacja
Dedecjusz M. - inna afiliacja
70p.
2.  Żyłka A., Dobruch-Sobczak K., Jędrzejczyk M., Piotrzkowska-Wróblewska H.E., Gałczyński J., Bakuła-Zalewska E., Dedecjus M., OR32-04 The Usefulness Of The Contrast-enhanced Ultrasound (CEUS) In Evaluating The Risk Of Malignancy In Thyroid Nodules, Journal of the Endocrine Society, ISSN: 2472-1972, DOI: 10.1210/jendso/bvad114.2059, Vol.7, No.Suplement 1, pp.1093-1095, 2023

Słowa kluczowe:
Thyroid, Ultrasound, CEUS

Afiliacje autorów:
Żyłka A. - inna afiliacja
Dobruch-Sobczak K. - IPPT PAN
Jędrzejczyk M. - inna afiliacja
Piotrzkowska-Wróblewska H.E. - IPPT PAN
Gałczyński J. - inna afiliacja
Bakuła-Zalewska E. - Institute of Oncology (PL)
Dedecjus M. - Institute of Oncology (PL)
20p.

Kategoria A Plus

IPPT PAN

logo ippt            ul. Pawińskiego 5B, 02-106 Warszawa
  +48 22 826 12 81 (centrala)
  +48 22 826 98 15
 

Znajdź nas

mapka
© Instytut Podstawowych Problemów Techniki Polskiej Akademii Nauk 2024